Generex - HIER GEHTS AB - IST AUSSER MIR NOCH WER DABEI??? - 500 Beiträge pro Seite

[hallodu_st]

Na wer außer mir ist noch dabei????

[granitbiss]

Habe 2 Mio. Stück zu 0,4

[iknowtheway]

4/26/2005 GENEREX BIOTECHNOLOGY RECEIVES AUSTRALIAN PATENT FOR NOVEL VACCINE TECHNOLOGY

Method of using peptides to enhance immune response has potential role in fighting cancer and pandemic influenza


TORONTO, Canada -- April 26, 2005 -- Generex Biotechnology Corp. (NasdaqSC: GNBT) announced today that its wholly owned subsidiary, Antigen Express, has received Australian Patent No. 778115 titled "Hybrid Peptides Modulate the Immune Response"; Antigen Express is designing and testing such vaccine peptides for the control of cancer and infectious diseases with a particular focus on the pandemic H5N1 influenza, which has been reported in South East Asia.

The specific award covers the use of vaccine peptides composed of the immunoregulatory Ii-Key peptide joined through a simple chemical spacer to MHC class II epitope peptides. Such hybrid peptides have about 200 times greater potency in vitro than the epitope-only peptide. In mouse vaccine experiments, such hybrids induce four-to-eight times greater T helper cell responses, when measured by special T helper cell assays.

A priority program for Generex and Antigen Express is the development of a vaccine using this technology to protect against pandemic H5N1 influenza. The Antigen Express vaccine could be used to prime T helper cell responses to a recombinant protein of H5 hemaglutinin. Such priming might be mandatory if recombinant H5 protein is in short supply, as some fear. Alternatively, the Antigen Express vaccine might be useful as a stand-alone vaccine if the pandemic progresses too swiftly.

The World Health Organization has warned that the H5N1 influenza might kill millions of persons worldwide, but vaccines against it cannot be easily raised because the virus is so strong that it kills the chicken embryos inside eggs in which vaccines are usually prepared. The current vaccine for the prevalent flu strains consists basically of H1 and H3 hemagglutinin proteins isolated from such inoculated eggs.

Development of the influenza H5 vaccine is being coordinated by Dr. Douglas Powell, Director of Immunobiology at Antigen Express. Powell trained at the National Institutes of Health with Dr. Tony Fauci and was a postdoctoral fellowship at the Gladstone Institute of Virology at University of California, San Francisco, with Dr. Warner Greene. He worked previously at DuPont Merck Pharmaceutical Co. (NYSE: DD) (NYSE: MRK), and most recently was Project Leader in Virology at Millennium Pharmaceuticals Inc. (Nasdaq: MLNM), working to identify novel T cellular targets for therapeutic intervention in HIV/AIDS.

Dr. Powell said, "I am optimistic that we have achieved a breakthrough in methods to prime a potent T cell response to individual MHC class II epitopes for various infectious diseases. In addition to protecting against pandemic influenza, I believe that similar experiments we are now pursuing with MHC class II epitopes from HIV gag and nef will lead to immunotherapeutic vaccines to protect against disease progression in HIV-positive individuals."

[iknowtheway]

Gibt wahrscheinlich den nächsten "bird flu" Rocker.
Aktie wird gerade erst entdeckt...........

[hallodu_st]

Bin heute wieder durchaus zufrieden. Tageshoch über einen USD hoffe so läufts weiter

[Niedersachsen]

sieht doch gut aus heute! schein wieder entdeckt zu werden.
relativ hohes volumen heute.

gruß

niedersachsen

[hallodu_st]

Wir können ganz zufrieden sein. Weiß irgendjemand warum die Umsätze und der Kurs so anzieht? Jeden Tag + 20 % ist doch nicht mehr normal???

[hallodu_st]

TORONTO, Oct. 4 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of
buccal drug delivery, today announced that Dr. Jaime Guevara-Aguirre, of the Institute of Endocrinology IEMYR in Quito,
Ecuador and one of the principal investigators in the Company`s on-going clinical trials of Oral-lyn(TM), its
proprietary oral insulin spray product, made a presentation of Oral-lyn(TM) clinical trials results at the 7th Hong
Kong Diabetes and Cardiovascular Risk Factors - East Meets West Symposium on October 2, 2005. Dr. Guevara-Aguirre made
an oral presentation of an abstract entitled "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type-2 Diabetes
Maintained on Glargine + Metformin - A Comparison with Placebo". The abstract was coauthored by Professor Itamar Raz
of Hadassah Hospital, Jerusalem, Israel (another Oral-lyn(TM) principal investigator) together with M. Kidron (also of
Hadassah Hospital) and M. Dubinsky and J. Wainstein of Wolfson Hospital, Holon, Israel.

In addition, Dr. Gerald Bernstein, the Company`s Vice-President for Medical Affairs, will be making the following
poster presentations at the Drug Discovery to Drug Development Global Partnering and New Science symposium in Mumbai,
India from October 5 - 7, 2005:

-- "A Series of Open-label Studies Comparing Various Formulations of
Orally Administered Insulin (Oral-lyn(TM)) in Patients with Type-1
Diabetes Mellitus (DM)", a study coauthored by Dr. Jaime Guevara-
Aguirre, Marco Guevara and Jeannette Saavedra of the Institute of
Endocrinology IEMYR in Quito, Ecuador;

-- "A 12-Day Comparison of Preprandial Humulin(R) vs. Oral-lyn(TM) in 10
Type 1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy",
a study coauthored by Dr. Jaime Guevara-Aguirre, Marco Guevara and
Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito,
Ecuador; and

-- "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type 2 Diabetes
Maintained on Glargine + Metformin - A Comparison with Placebo," a
study coauthored by Professor Itamar Raz of Hadassah Hospital,
Jerusalem, Israel together with M. Kidron (also of Hadassah Hospital)
and M. Dubinsky and J. Wainstein of Wolfson Hospital, Holon, Israel.



"The continuing acceptance at these significant scientific symposia of Oral-lyn(TM) studies is indicative of the
increasing recognition in the global scientific community of our product`s potential for providing a vast improvement
in the quality of life of patients with diabetes," said Anna Gluskin, the Company`s President & Chief Executive
Officer. "In addition, we welcome the increased exposure of Oral-lyn(TM) in the scientific communities in China and
India, two potentially enormous markets for the product."

[hallodu_st]

Grundsätzlich stellen die also ein insulin-Spray her, dass oral eingenommen werden kann, also nicht gespritzt wird... soviel ist klar.

Naja, warte noch ab, bevor ich verkaufe....

[therman]

Hallo,

mehr Infos zu der Aktie:
Thread: GENEREX: EIN MILLIARDENMARKT!!!!

GNBT hat eine Tochterfirma, die einen Impfstoff gegen die
Vogelgrippe entwickelt, deshalb der starke Kursanstieg.

[Niedersachsen]

schade eigentlich!!!
jeden abend der gleiche mist, kacken immer wieder unter einen euro ab.
fehlt noch ein bisschen der nachhaltige ausbruch über 1,--.

[hallodu_st]

SK war doch ein USD, wieder 11 % Plus...

Heute sehen wir die 1,20 sicher nochmal...

[kgv1]

Check out NVAX auch
Kgv1

[hallodu_st]

Tageshoch: 1,25 USD
mom: 1,17 USD mal wieder fast 10 %

[hallodu_st]

Aktien festhalten

31-Oct-2005

Annual Report



Item 7. Managements Discussion and Analysis of Financial Condition and Results
of
Operations.
Corporate History

We were incorporated in Delaware in September 1997 for the purpose of acquiring Generex Pharmaceuticals, Inc., a Canadian corporation formed in November 1995 to engage in pharmaceutical and biotechnological research and other activities. Our acquisition of Generex Pharmaceuticals was completed in October 1997 in a transaction in which the holders of all outstanding shares of Generex Pharmaceuticals exchanged their shares for shares of our common stock.

In January 1998, we participated in a "reverse acquisition" with Green Mt. P.
S., Inc., a previously inactive Idaho corporation formed in 1983. As a result of this transaction, our shareholders (the former shareholders of Generex Pharmaceuticals) acquired a majority (approximately 90%) of the outstanding capital stock of Green Mt., we became a wholly-owned subsidiary of Green Mt., Green Mt. changed its corporate name to Generex Biotechnology Corporation ("Generex Idaho"), and we changed our corporate name to GB Delaware, Inc. Because the reverse acquisition resulted in our shareholders becoming the majority holders of Generex Idaho, we were treated as the acquiring corporation in the transaction for accounting purposes. Thus, our historical financial statements, which essentially represented the historical financial statements of Generex Pharmaceuticals, were deemed to be the historical financial statements of Generex Idaho.

In April 1999, we completed a reorganization in which we merged with Generex Idaho. In this transaction, all outstanding shares of Generex Idaho were converted into our shares, Generex Idaho ceased to exist as a separate entity, and we changed our corporate name back to "Generex Biotechnology Corporation." This reorganization did not result in any material change in our historical financial statements or current financial reporting.

In August 2003, we acquired Antigen Express, Inc. Antigen is engaged in the research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune and allergic diseases.

Business History

We are engaged primarily in the research and development of drug delivery technologies. Our primary focus at the present time is our proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator.



--------------------------------------------------------------------------------
Our first product is an insulin formulation that is administered as a fine spray into the oral cavity using a hand-held aerosol spray applicator. Between January 1999 and September 2000, we conducted limited clinical trials on this product in the United States, Canada and Europe. In September 2000, we entered into an agreement (the "Development and License Agreement") to develop this product with Eli Lilly and Company ("Lilly"). To date, over 1,100 patients with diabetes have been dosed with our oral insulin product at approved facilities in seven countries. We conducted several clinical trials with insulin supplied by Lilly under our Development and License Agreement. Lilly did not, however, authorize or conduct any clinical trials or provide financial support for those trials. We did receive a $1,000,000 upfront payment from Lilly. On May 23, 2003, we announced that we had agreed with Lilly to end the Development and License Agreement for the development and commercialization of buccal delivery of insulin. On November 5, 2003, we entered into a termination agreement with Lilly terminating the Development and License Agreement, effective as of June 2, 2003. In accordance with the termination agreement, we retained all of the intellectual property and commercialization rights with respect to buccal spray drug delivery technology, and we have the continuing right to develop and commercialize the product. We also entered into a Bulk Supply Agreement (the "Bulk Supply Agreement") for the sale of human insulin crystals by Lilly to us over a three-year period.
In January 2001, we established a joint venture with Elan International Services, Ltd. ("EIS"), a wholly-owned subsidiary of Elan Corporation, plc (EIS and Elan Corporation, plc being collectively referred to as "Elan"), to pursue the application of certain of our and Elan`s drug delivery technologies, including our platform technology for the buccal delivery of pharmaceutical products, for the treatment of prostate cancer, endometriosis and/or the suppression of testosterone and estrogen. In January 2002, we and Elan agreed to expand the joint venture to encompass the buccal delivery of morphine for the treatment of pain and agreed to pursue buccal morphine as the initial pharmaceutical product for development under Generex (Bermuda) Ltd., the entity through which the joint venture was being conducted. This expansion of the joint venture occurred after we successfully completed a proof of concept clinical study of morphine delivery using our proprietary buccal delivery technology.

In connection with the joint venture, EIS purchased 1,000 shares of our Series A Preferred Stock for $12,015,000, which EIS transferred, shortly thereafter, to Elan Pharmaceuticals Investment III, an affiliate of Elan ("EPIL III"). We applied the proceeds from the sale of the Series A Preferred Stock to subscribe for an 80.1% equity ownership interest in Generex (Bermuda), Ltd. EIS paid in capital of $2,985,000 to subscribe for a 19.9% equity ownership interest in the joint venture entity. In accordance with the terms of the Series A Preferred Stock, if any shares of Series A Preferred Stock were to be outstanding on January 16, 2007, we would have been required to redeem the shares of Series A Preferred Stock at a redemption price equal to the aggregate Series A Preferred Stock liquidation preference, either in cash, or in shares of common stock with a fair market value equal to the redemption price. Alternatively, the Series A Preferred Stock could have been converted, under certain conditions, into shares of our common stock. EIS also purchased 344,116 shares of our common stock for $5,000,000. We were permitted to use the proceeds of this sale for any corporate purpose.

On December 27, 2004, we entered into an agreement (the "Termination Agreement") with Elan, whereby we and Elan agreed to terminate the joint venture through Generex (Bermuda) Ltd. Pursuant to the terms of the Termination Agreement, (i) except for a common stock purchase warrant that was issued by us to Elan, which was amended to permit Elan or any other holder thereof to transfer the warrant without our consent, the parties agreed to terminate all agreements entered into in connection with the joint venture, and (ii) Elan agreed to transfer all shares of capital stock of Generex (Bermuda) owned by it to us. Accordingly, all rights granted by each party to the other terminated, including, without limitation, Elan`s right to appoint a member to our Board of Directors, all other rights granted under the terms of the joint venture terminated, each party retained its intellectual property rights, we obtained full ownership of Generex (Bermuda), and all representatives of Elan who were officers and/or directors of Generex (Bermuda) resigned.



--------------------------------------------------------------------------------
In connection with negotiating the Termination Agreement, EPIL III approached us for consent to transfer the Series A Preferred Stock by way of an auction process. Although we provided our consent to the transfer, it was contingent upon EPIL III agreeing to satisfy the following conditions: (i) the auction process could conclude no later than December 15, 2004 and EPIL III`s disposition of the shares could conclude no later than December 31, 2004 (the "Closing Date"), (ii) the buyer had to immediately convert the Series A Preferred Stock at the voluntary conversion price of $25.77 (calculated pursuant to the terms of the certificate of designation for the Series A Preferred Stock resulting in the issuance of 534,085 shares of common stock), (iii) EPIL III`s registration rights could not be transferred, and (iv) for a period of two (2) years after the Closing Date, the purchaser of the Series A Preferred Stock could not transfer the shares of common stock issuable upon conversion thereof and we would have the right to redeem the shares of common stock at a per share price of 150% of the average closing price of the common stock on The Nasdaq SmallCap Market for the twenty (20) days immediately preceding the Closing Date. On or about December 15, 2004, EPIL III conducted the auction and received an offer to buy the shares of Series A Preferred Stock. On or about December 31, 2004, EPIL III sold the shares of Series A Preferred Stock, and the purchaser thereof immediately converted the Series A Preferred Stock into shares of our common stock.
The conversion of the Series A Preferred Stock was particularly critical because the mandatory redemption feature required us to classify the Series A Preferred Stock as approximately $14,300,000 of mezzanine equity. Upon conversion of the Series A Preferred Stock, however, we were able to reclassify the approximately $14,300,000 of mezzanine equity as common equity on our balance sheet. This, in turn, allowed us to regain compliance with NASDAQ`s Marketplace Rule 4310(c)(2)(B), which requires us to have a minimum of $2,500,000 in stockholders` equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years.

In August 2003, we acquired Antigen Express, Inc. Antigen is engaged in the research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune and allergic diseases.

Our immunomedicine products work by stimulating the immune system to either attack offending agents (i.e., cancer cells, bacteria, and viruses) or to stop attacking benign elements (i.e., self proteins and allergens). Our immunomedicine products are based on two platform technologies that were discovered by an executive officer of Antigen, the Ii-Key hybrid peptides and Ii-Suppression. The immunomedicine products are in the pre-clinical stage of development, and trials in human patients are not expected for at least six months. Development efforts are underway in melanoma, breast cancer, prostate cancer, HIV, influenza virus, smallpox, SARS and Type I diabetes mellitus. We are establishing collaborations with clinical investigators at academic centers to advance the technology, with the ultimate goal of conducting human clinical testing.

With the anticipated launch of commercial sales of our oral insulin product in Ecuador in 2005, we expect to receive revenues from product sales in the fiscal year ending July 31, 2006. We do not expect this revenue to be sufficient for all of our cash needs during the year. In the past we were able to fund Antigen expenses with some revenue from research grants for Antigen`s immunomedicine products. During the fiscal year ended July 31, 2005, we received a total of $392,112 in such research grants, and we have received a total of $1,019,296 in such research grants. We do not expect to receive such grants on the going forward basis. We expect to satisfy the majority of our cash needs during the current year from capital raised through equity financings.



--------------------------------------------------------------------------------
Disclosure Regarding Research and Development Projects
Our major research and development projects are the refinement of our basic buccal delivery technology, our buccal insulin project and our buccal morphine product.

Both our insulin product and our morphine product are in clinical trials. During last fiscal year we did not expend resources to further our buccal morphine product. In Canada, we are in the process of finalizing submission to Canadian HPB to start Phase III trials for our insulin. In order to obtain FDA and Canadian HPB approval for any of our product candidates, we will be required to complete "Phase III" trials which involve testing our product with a large number of patients over a significant period of time. The conduct of Phase III trials will require significantly greater funds than we either have on hand or have experience in raising in any year or two years` time. We will therefore need to receive funding from a corporate collaborator, or engage in fundraising on a scale with which we have no experience.

Our insulin product, Oral-lyn, was approved for commercial sale by drug regulatory authorities in Ecuador in early May 2005. It is our intention that our South American joint venture partner, PharmaBrand S.A., will handle the commercial launch of Oral-lyn in Ecuador, subject to obtaining financing needed for launch and a suitable production facility. We will require substantial amounts in additional funding to successfully launch Oral-lyn on a commercial basis in Ecuador.

Because of various uncertainties, we cannot predict the timing of completion and commercialization of our buccal insulin or buccal morphine products. These uncertainties include the success of current studies, our ability to obtain the required financing and the time required to obtain regulatory approval even if our research and development efforts are completed and successful. For the same reasons, we cannot predict when any products may begin to produce net cash inflows.

Most of our buccal delivery research and development activities to date have involved developing our platform technology for use with insulin and morphine. Insubstantial amounts have been expended on projects with other drugs, and those projects involved a substantial amount of platform technology development. Therefore, in the past, we have not made significant distinctions in the accounting for research and development expenses among products, as a significant portion of all research has involved improvements to the platform technology in connection with insulin, which may benefit all of our potential products. During fiscal 2005, approximately 84% of our $7,750,731 in research expenses was attributable to insulin and platform technology development, and did not spend any money on morphine and fentanyl projects. As morphine and fentanyl are both narcotic painkillers, the research is related. In the same period of fiscal 2004, approximately 90% of our $8,522,984 of research and development was expended for insulin and platform technology, and approximately 1% for morphine and fentanyl.

Approximately 16% or $1,210,512 of our research and development expenses for the fiscal year ended July 31, 2005 were related to Antigen`s immunomedicine products compared to approximately 11% or $937,385 for the fiscal year ended July 31, 2004. Because these products are in a very early, pre-clinical stage of development, all of the expenses were accounted for as basic research and no distinctions were made as to particular products. Because of the early stage of development, we cannot predict the timing of completion of any products arising from this technology, or when products from this technology might begin producing revenues.



--------------------------------------------------------------------------------
Developments in Fiscal 2005
On August 10, 2004, we issued an aggregate 620,000 shares of our common stock and 500,000 warrants to purchase our common stock to certain consultants in exchange for financial services recognizing expense of $1,090,800 to financial services.

On August 26, 2004, Dr. Pankaj Modi resigned from his position as an officer of Generex. Also, on August 26, 2004, Dr. Modi notified us that the Consulting Agreement between Dr. Modi and us would terminate effective August 25, 2005. We do not believe that Dr. Modi`s resignation or the termination of his Consulting Agreement with us has, or will, materially adversely affect us.

On October 26, 2004, we granted a total of 1,942,000 options to purchase shares of our common stock to certain employees and consultants at $0.94 per share and 150,000 options to an employee to purchase shares of our common stock at $1.10 per share. The options issued to non-employees resulted in $75,600 charge to operations.

On November 10, 2004, we entered into a Securities Purchase Agreement with four accredited investors for a private placement of 6% Secured Convertible Debentures (the Debentures) and warrants for an aggregate purchase price of $4,000,000. We completed this private placement on November 12, 2004. The Debentures have a term of fifteen months and amortize over thirteen months in thirteen equal monthly installments beginning on the first day of the third month following their issuance. Interest on the principal amount outstanding will accrue at a rate of six percent (6%) per annum. We may pay principal and accrued interest in cash or, at our option, in shares of our common stock. If we elect to pay principal and interest in shares of our common stock, the value of each share of common stock will be equal to the lesser of (i) $0.82 and (ii) ninety percent (90%) of the average of the twenty (20) trading day volume weighted average price for the common stock for the twenty (20) trading day period immediately preceding the date of payment. At the option of the holder of each Debenture, the principal amount outstanding under each Debenture is initially convertible at any time after the closing of the private placement into shares of our common stock at a conversion price of $0.82. The conversion price of each Debenture is based on the average of the ten (10) trading day volume weighted average price for our common stock for the ten (10) trading day period immediately preceding the date definitive agreements were signed. The warrants are initially exercisable into the same number of shares of our common stock initially issuable upon conversion of the Debentures. The initial exercise price of each warrant is equal to 110% of the conversion price of the Debentures, or $0.91. The conversion price of the Debentures and the exercise price of the warrants are each subject to an anti-dilution adjustment upon the issuance by us of securities at a price per share less than the then conversion price or exercise price, as applicable. In accordance with the terms of the private placement, we were required to register for resale the shares of common stock issuable upon conversion of the Debentures and upon exercise of the warrants. On December 15, 2004, we filed a Registration Statement on Form S-3 (File No. 333-121309) in connection with this transaction. The Registration Statement became effective on January 24, 2005.

In connection with the November 12, 2004 transaction, we granted an Additional Investment Right to each investor. Pursuant to the terms of each Additional Investment Right, each investor has the right at any time prior to January 24, 2006, to purchase on the same terms and conditions as the private placement, up to the same number of Debentures and warrants purchased by such investor at the closing of the private placement. In addition, we paid to a placement agent (i) a cash fee equal to seven percent (7%) of the gross proceeds received by us and
(ii) warrants exercisable into approximately 145,000 shares of our common stock at the same exercise price as the investors` warrants.



--------------------------------------------------------------------------------
The aggregate number of shares of common stock issuable pursuant to the November 12, 2004 transaction exceeds 19.99% of the outstanding shares of our common stock prior to such issuance. Because the rules and regulations of The Nasdaq Stock Market prohibit, under certain circumstances, the issuance, without prior stockholder approval, of shares of common stock in excess of 19.99% of an issuer`s outstanding common stock prior to such issuance, certain insiders entered into a voting agreement with the investors, whereby such insiders agreed to vote at the 2005 Annual Meeting of Stockholders all shares of our common stock held by them in favor of authorizing the issuance of an amount of shares of our common stock in excess of 19.99% of the outstanding common stock prior to consummating the transaction. As discussed above in Part I - Item 4. Submission of Matters to a Vote of Security Holders, at the 2005 Annual Meeting of Stockholders, this proposal was approved by our stockholders. We undertook this offering in reliance upon Rule 506 of Regulation D and Section 18(b)(4)(D) of the Securities Act.
On November 19, 2004, we received notice from The Nasdaq Stock Market informing us that we did not comply with Marketplace Rule 4310(c)(2)(B), which requires us to have a minimum of $2,500,000 in stockholders` equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. However, upon consummation in December 2004 of the transactions contemplated by a Termination Agreement we entered into with Elan, as more fully described below, we regained compliance with Marketplace Rule 4310(c)(2)(B).

On November 24, 2004, we received notice from The Nasdaq Stock Market informing us that we did not comply with Marketplace Rule 4310(c)(4), which requires us to have a minimum bid price per share of at least $1.00 for thirty (30) consecutive business days. In accordance with Marketplace Rule 4310(c)(8)(D), we had 180 calendar days from the date of the notice, or until May 23, 2005, to regain compliance with the Rule. As more fully described below, because we met all initial inclusion criteria for the SmallCap Market set forth in Marketplace Rule 4310(c), except for bid price, as of May 23, 2005, we have until November 21, 2005 to regain compliance with Marketplace Rule 4310(c)(4).

On December 27, 2004, we entered into an agreement (the "Termination Agreement") with Elan, whereby we and Elan agreed to terminate the joint venture through Generex (Bermuda) Ltd. Pursuant to the terms of the Termination Agreement, (i) except for a common stock purchase warrant that was issued by us to Elan, which was amended to permit Elan or any other holder thereof to transfer the warrant without our consent, the parties agreed to terminate all agreements entered into in connection with the joint venture, and (ii) Elan agreed to transfer all shares of capital stock of Generex (Bermuda) owned by it to us. Accordingly, all rights granted by each party to the other terminated, including, without limitation, Elan`s right to appoint a member to our Board of Directors, all other rights granted under the terms of the joint venture terminated, each party retained its intellectual property rights, we obtained full ownership of Generex (Bermuda), and all representatives of Elan who were officers and/or directors of Generex (Bermuda) resigned.

In connection with negotiating the Termination Agreement, EPIL III approached us for consent to transfer the Series A Preferred Stock by way of an auction process. Although we provided our consent to the transfer, it was contingent upon EPIL III agreeing to satisfy the following conditions: (i) the auction process could conclude no later than December 15, 2004 and EPIL III`s disposition of the shares could conclude no later than December 31, 2004 (the "Closing Date"), (ii) the buyer had to immediately convert the Series A Preferred Stock at the voluntary conversion price of $25.77 (calculated pursuant to the terms of the certificate of designation for the Series A Preferred Stock resulting in the issuance of 534,085 shares of common stock), (iii) EPIL III`s registration rights could not be transferred, and (iv) for a period of two (2) years after the Closing Date, the purchaser of the Series A Preferred Stock could not transfer the shares of common stock issuable upon conversion thereof and we would have the right to redeem the shares of common stock at a per share price of 150% of the average closing price of the common stock on The Nasdaq SmallCap Market for the twenty (20) days immediately preceding the Closing Date. On or about December 15, 2004, EPIL III conducted the auction and received an offer to buy the shares of Series A Preferred Stock. On or about December 31, 2004, EPIL III sold the shares of Series A Preferred Stock, and the purchaser thereof immediately converted the Series A Preferred Stock into shares of our common stock.



--------------------------------------------------------------------------------
The conversion of the Series A Preferred Stock was particularly critical because the mandatory redemption feature required us to classify the Series A Preferred Stock as approximately $14,300,000 of mezzanine equity. Upon conversion of the Series A Preferred Stock, however, we were able to reclassify the approximately $14,300,000 of mezzanine equity as common equity on our balance sheet. This, in turn, allowed us to regain compliance with NASDAQ`s Marketplace Rule 4310(c)(2)(B), which requires us to have a minimum of $2,500,000 in stockholders` equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years.
In February 2005, a consultant commenced an action in the Ontario Superior Court of Justice against us seeking approximately $600,000 in damages for alleged contract breaches in respect of unpaid remuneration and other compensation allegedly owed to him. We are of the view that the claims are wholly without merit and intends to defend this action vigorously. We are not able to predict the ultimate outcome of this legal proceeding at the present time or estimate an amount or range of potential loss, if any, from this legal proceeding.

We entered into a Promissory Note and Agreement with Cranshire Capital, L.P. ("Cranshire") on March 28, 2005 and entered into a Promissory Note and Agreement with Omicron Master Trust ("Omicron") on April 6, 2005 pursuant to which Cranshire and Omicron loaned us the principal amount of $500,000 and $100,000, respectively. As additional consideration for the loans from Cranshire and Omicron, we issued on April 28, 2005 a warrant to Cranshire to purchase an aggregate of 1,219,512 shares of our common stock and a warrant to Omicron to purchase an aggregate of 243,902 shares of our common stock, both of which will expire on April 27, 2010. The terms and conditions of the loans from Cranshire and Omicron, as well as the rights of Cranshire and Omicron under the warrants, are described below under the caption Financial Condition, Liquidity and Resources of this Part II - Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

On March 30, 2005, we entered into an Assistance Agreement with Eckert Seamans Cherin & Mellott, LLC, ("Eckert Seamans"), pursuant to which Eckert Seamans advanced us funds in the amount of $325,179 for the sole purpose of making the interest payment and the monthly redemption payment due on March 31, 2005 and April 1, 2005, respectively, under our 6% Secured Convertible Debentures. The terms and conditions of the Assistance Agreement with Eckert Seamans, as well as our obligations with respect to the 6% Secured Convertible Debentures, are described below under the caption Financial Condition, Liquidity and Resources of this Part II - Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

On March 31, 2005 Generex Pharmaceuticals, Inc. (GPI), our wholly-owned subsidiary, entered into a mortgage loan transaction pursuant to which GPI borrowed approximately $183,804 ($230,000 CND) (the March GPI Loan). The net proceeds to GPI after fees and disbursements were approximately $159,596 ($200,800 CND). The March GPI Loan was secured by, inter alia, a charge registered against real property owned by GPI. The loan was for a term of two years with an annual interest rate of 13.5 % calculated monthly.

[Niedersachsen]

weiß jemand warum die umsätze gerade so abgehen?
gibt es irgendeine meldung?

[Xepher]

irgendwas geht da ab!!!! ich weis nur nicht was! es scheint als würde sich jemand eindecken....
es gibt nur käufe und der kurs bleibt kleben.....
großes volumen heute....wow!

[Xepher]

heute kam dies hier:


Generex Scientist Presents Results of Pandemic Influenza Vaccine Program at Washington Conference Highlighting Strategic Advances in Vaccines
Novel Vaccine Technology Boosts T Helper Cell Responses to Asian Bird Flu Influenza



TORONTO -- (MARKET WIRE) -- 11/04/05 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that the Chief Scientific Officer of Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, made a presentation earlier today at a national conference regarding the Company`s program for accelerated development of its novel vaccine for pandemic influenza.

Dr. Robert Humphreys, M.D., Ph.D., the Chief Scientific Officer of Antigen Express, presented results of an ongoing, prioritized program to develop a novel approach to vaccinating against pandemic influenza at the Third Annual Conference on Vaccines in Washington, D.C. Many leaders in vaccine development in the U.S. government, industry, and academic centers are attending the conference.

Dr. Humphreys has spent his career understanding how antigenic peptides are presented to the immune system and how novel treatments for disease might be designed. As a research fellow at Harvard University, he first isolated the MHC class II molecules, which present antigenic peptides to T helper cells to regulate the immune response. Subsequently, as Professor of Pharmacology and Medicine at the University of Massachusetts Medical School, Dr. Humphreys discovered the immunoregulatory Ii protein that binds naturally into the antigenic peptide-binding site of those MHC class II molecules. He showed that a segment of the Ii protein, the Ii-Key peptide, acts on MHC class II molecules to regulate peptide binding or exchange. More recently, he and his colleagues at Antigen Express have discovered and patented novel hybrid peptides in which the immunoregulatory Ii-Key peptide is linked covalently to antigenic epitopes. Many papers from Antigen Express scientists and collaborators demonstrate the potential of such vaccine peptides.

The practical result of these discoveries is to provide a very flexible and rapid means for developing peptide vaccines that stimulate T helper cells. Once a target protein is identified, straightforward methods are available for predicting those fragments with the greatest potential to stimulate T helper cells, linking them to Ii-Key for maximized potency and running biological screening assays to identify lead candidates. In addition to this technology base, the Company has advanced specific product candidates for infectious diseases and cancer towards the clinic. The most advanced of these is an Ii-Key hybrid of a peptide found in the cancer-associated HER-2/neu protein. This compound is currently in Phase I clinical trials at the Walter Reed Army Medical Center. Under the leadership of Dr. Eric von Hofe, President of Antigen Express, Generex has organized its forces to speed development of a novel vaccine to protect against the H5N1 avian influenza.

A major drawback to current vaccine development efforts is the inability to manufacture enough vaccine in the event of an avian flu pandemic. Current estimates are that the total production capacity of the world for producing an avian flu vaccine using traditional methods is less than 40 million doses, at the cost of several 100 million dollars. A compounding problem in developing vaccines for the avian flu is that two doses are required to achieve protective immunity given that people have never been exposed to a flu virus similar enough to impart even partial immunological protection.

The great advantage of the Antigen Express vaccine is the ability to expand and strengthen the T helper cell response. T helper cell stimulation is pivotal in developing an effective immune response to novel agents. In addition to increasing the overall response to a lower dose of classically produced vaccine, it is also expected that the vaccine hybrids will afford some significant degree of protection in people who have received no other vaccine. The Ii-Key/H5 hybrids can be synthesized inexpensively and in large quantities.

Anna Gluskin, President & Chief Executive Officer of Generex Biotechnology said: "I thank all of my colleagues at Antigen Express for their outstanding effort in advancing this vaccine toward clinical trials. The theoretical reasons why these special vaccine hybrid peptides might be very effective as a stand-alone as well as in allowing lower doses of recombinant H5 protein to be used are well established in many peer-reviewed papers. Data from their H5 preclinical studies are beginning to bear this out. We plan, as fast as possible, to bring these novel compounds to protect against pandemic influenza into the clinic."

[Xepher]

so jetzt haben wir die hammer news!!!!
waiting for monday!!!!!!! wow


November 06, 2005
Company takes synthetic tack in fighting flu

By Susan Williams
Staff writer
A vaccine now in development may stop a possible pandemic of avian influenza, and an Oak Hill native serves on the board of directors of a company whose subsidiary created the vaccine.

Mindy Allport-Settle said last week that Antigen Express’ vaccine is completely synthetic, and that they have the ability to generate it quickly. Allport-Settle is a director of Toronto-based Generex Biotechnology Corp., the parent company of Antigen Express, which is based in Massachusetts.

More than 30 years ago, Antigen Express was founded by Robert Humphries, an immunologist who began working on “T helper” cells in the body. This work led to a breast cancer vaccine now in clinical trials at Walter Reed Army Medical Center.

- advertisement -

Scientists at Antigen began experimenting and wondering if the breast cancer vaccine would have other applications.

Antigen President Eric von Hofe said they learned T-helper cells remember when the body has been attacked by disease, so if the cells encounter that disease again “this triggers a memory of the event, and the cells know they have encountered the disease before, and they are ready to go. We’ve got our response to it.”

At Antigen, scientists began to develop a proprietary technology that stimulates the cell response to help the cells fight diseases better.

“We are immunizing with T-helper cells that educate the immune system of the body,” he said.

In traditional laboratories, von Hofe explained, workers grow vaccines in chicken eggs. This is both slow and impure, he said.

He said the world production, under the best of conditions, would be to produce 40 million doses of vaccine a year.

Because Antigen uses synthetic materials that can be adapted to labs all around the world, they could produce “100 million doses of vaccine in a few months,” he said.

Among scientists studying a possible pandemic, von Hofe said, “Everyone agrees it is not a matter of if, but when.”

Allport-Settle said company officials went to Washington, D.C., recently to talk with members of Congress. They are hoping to get additional funding and help with the approval process at the U.S. Food and Drug Administration.

Anna Gluskin, president and chief executive officer of Generex, believes the new vaccine can be manufactured easily and inexpensively in existing manufacturing plants.

To contact staff writer Susan Williams, use e-mail or call 348-5112.

[wiskas]

aktuell $ 1,35

[hallodu_st]

1,39...

Schade bin heute bei 1,32 raus... hat mir zu zögerlich begonnen.

Naja, wird schon noch mal auf 1,20 zurückgehen (hatten wir noch immer so), dann baue ich wieder auf...

[Niedersachsen]

hoffen wir mal, das diesmal der weg direkt nach oben geht.
das volumen und der kurs spricht im moment für sich.

gutes nächtle,

niedersachsen

[Xepher]

guten morgen

das sentiment der amis schaut generell so aus:

Re: Read the filing, folks!! Its great
by: cschroeder13
Long-Term Sentiment: Strong Buy 11/07/05 05:03 pm
Msg: 28519 of 28864

Everyone knows this news is great it is an update to last weeks news on the 6.4 million dollars, now it is 7.9 million dollars instead, 1.5 million more in cash without dilution, read last weeks PR, we should gap and run huge tomorrow. Better and better news every day with GNBT.

[Xepher]

das kam gestern



Generex Biotechnology Announces Filing of Annual Report on Form 10-K and Related Auditor Opinions
Monday November 7, 4:15 pm ET

Subsequent to the Completion of the Form 10-K, the Company Received $7.9 Million Through the Exercise of Warrants

TORONTO--(MARKET WIRE)--Nov 7, 2005 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that on October 31, 2005 it filed its Annual Report on Form 10-K in respect of its fiscal year ended July 31, 2005. The Form 10-K includes the report of BDO Dunwoody LLP, its independent registered public accounting firm, with respect to the Company`s financial statements for the fiscal year ended July 31, 2005. The report of BDO Dunwoody LLP included an explanatory paragraph regarding the company`s ability to continue as a going concern given its recurring net losses and negative cash flows from operations and its working capital deficiency.
ADVERTISEMENT

Subsequent to the completion of the Form 10-K, Generex received an aggregate of $7.9 million through the exercise of outstanding warrants, leaving the Company in its strongest cash position since July 31, 2003.

This release is being issued to comply with NASDAQ Marketplace Rule 4350(b), which requires that a public announcement be made regarding the receipt of an audit opinion that contains a going concern qualification.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company`s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company`s proprietary RapidMist(TM) device. The Company`s flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.

[Xepher]

hm!!??? mir kommt vor als wäre diese aktie bei uns in germany noch recht unentdeckt
finde ich sehr gut.....hoffe es bleibt auch noch ein weilchen so!!

[hallodu_st]

So bin für 1,30 USD wieder schön fett rein. Die 0,02 Cent differenz auf meinen Verkauf gestern bringen trotz Spesen mal wieder ein paar Euro...

Naja. Heute gehn wir die 1,40 an - vermute ich mal..

[hallodu_st]

Nasdaq Realtime:


GENEREX BIOTECH CORP (NasdaqSC:GNBT)

Last Trade: 1.33
Trade Time: 9:42AM ET
Change: 0.03 (2.21%)
Prev Close: 1.36
Open: 1.35
Bid: 1.33 x 11200
Ask: 1.33 x 1000
1y Target Est: N/A

Day`s Range: 1.29 - 1.35
52wk Range: 0.51 - 1.51
Volume: 1,064,792
Avg Vol (3m): 2,389,010
Market Cap: 62.28M
P/E (ttm): N/A
EPS (ttm): -0.66
Div & Yield: N/A (N/A)

[hallodu_st]

Achtung in Wenigen Sekunden Kauf bei 1,30, da schmeißt einer 150 K

LG

[hallodu_st]

Vorbörsliche News:

)--Nov 9, 2005 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, has made proposals for co-development of the Antigen Express novel H5N1 avian influenza vaccine in China following a trip to Beijing by Dr. Minzhen Xu, the Antigen Express Vice-President of Biology.
ADVERTISEMENT


Proposals were made to: Professor Hualan Chen of the Harbin Veterinary Research Institute; Ms. Nan Wang, Vice General Manager of Sinovac Biotech Co., Ltd.; and Professor Bing Sun of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All have an interest in vaccine development for the H5N1 avian influenza in China.

The vaccine technology being employed at Antigen Express for the potentially pandemic avian influenza is the same as that for its novel immunotherapeutic cancer vaccine currently in clinical trials. "The basis of this technology lies in identifying portions of a specific disease-associated protein that are capable of stimulating T-helper cells which are subsequently modified to augment their vaccine potency," explained Dr. Xu. "T-helper cells play a critical role in generating an immune response to a novel foreign agent, directing other immune cells against that threat, and in establishing immunological `memory` of that agent. Once these cells are stimulated, it is much easier to mount an effective response against an agent such as the H5N1 influenza virus."

Antigen Express has extant collaborations in China focusing on SARS and a novel immunotherapy strategy for patients with acute myeloid leukemia. "These relationships provide a convenient platform for expanding into avian influenza in China," said Dr. Eric von Hofe, President of Antigen Express. "The danger posed by avian influenza in China is more acute, given the recent outbreaks of the H5N1 strain in birds there, and they face the same supply limitations on traditional vaccines as are faced throughout the world. Furthermore, vaccinating people close to hot spots of H5N1 outbreaks is recognized as the best way to control a possible pandemic." Current estimates are that the world capacity per year for production of H5N1 vaccine by traditional methods would protect less than 40 million people.

Scientists at Antigen Express are developing a vaccine for the potentially pandemic Asian bird flu utilizing highly conserved fragments of the H5 protein to stimulate potent T-helper cell activity. The H5 fragments are modified using a portion of an immunoregulatory protein (termed Ii-Key) that greatly facilitates their ability to stimulate T-helper cell responses specific to the H5N1 strain. The vaccine peptides have been selected for their likelihood of being both potent and active in more than 90% of the population. This technology has the advantage of being applicable to any novel agent or protein once one has sequence information. As vaccine peptides are manufactured by entirely synthetic means they can be produced rapidly, relatively inexpensively, and in large quantities (hundreds of millions of doses).

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company`s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company`s proprietary RapidMist(TM) device. The Company`s flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex Web site at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

[hallodu_st]

Vorbörslich:

Last Trade: 1,38

Realtime-Vorbörslich: Ask bis 1,37

Bid Orders
Price Order Size
1.37 1000
1.36 3000
1.34 2900
1.33 6300
1.32 2000
1.20 7500
1.19 3000
1.18 1500
0.90 10000
0.59 4000

Ask Orders
Price Order Size
1.38 1050
1.39 4000
1.40 3500
1.42 50
1.50 5000
1.60 5000
1.70 500
1.80 5000
1.89 4000
2.08 1000

[Xepher]

nur so zum spaß

fällt euch da was auf?

http://www.pharmabrand.com.ec/htm/principal.htm

[schmacki]

Das Produkt muss sich erst mal verkaufen,also Warten!!
Zur Zeit,ist alles auf Vogelgrippe fokusiert...
Bin auf heutigen Handelsverlauf gespannt

[hallodu_st]

Schaut heute nicht so rosig aus

1,15 RT

[hallodu_st]

Fast jeden Tag ne Meldung, meist sehr positiv, hurra...

Mein Abstauber-Limit @1USD wurde am Freitag bedient. Sehe für diese Woche sicher wieder höhere Kurse...

[hallodu_st]

Lt. US-Board-Friends Shorties angriff.

Unterstützung bei 0,95, 0,87 und 0,72 USD.

Nur als Info... falls hier jemand das liest...

[Niedersachsen]

bis 0,95 habe ich ja nichts dagegen, aber weiter runter muß
nicht sein.

gruß

niedersachsen

[Xepher]

Wir bleiben an der NASDAQ!!!!!!!!!!!!!!!!!!!!!!!!!


Generex Biotechnology Achieves Compliance With Nasdaq Capital Market Continued Listing Requirements


TORONTO -- (MARKET WIRE) -- 11/15/05 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that on November 14, 2005 it received written confirmation from the Nasdaq Stock Market that the Company has achieved compliance with the continued listing requirements in accordance with Nasdaq Marketplace Rule 4310(c)(4).

[Xepher]

hallo ??? ist da jemand???

GNBT geht ab und keiner freut sich mit mir!!!

[formentum]

Freu mich, diese Gnbt aus Canada könnte bald richtig ausbrechen und zuerst 2 Dollar ansteuern, haben das Zeug zum Höhenflieger.

[Pumafreddy]

So richtig freude kann nicht aufkommen, da ich eher von einer techn. Erholung nach den starken Verlusten der vergangenen Tage ausgehe. Ich hoffe ich habe unrecht.
Bin vor ein paar Tagen eingestiegen und immer noch dick im Minus.

[Niedersachsen]

gehe nicht von einer technischen erhohlung aus, sondern da waren eher shortys am werk.
nun heizt das thema vogelgrippe wieder an.
und da ist noch jede menge phantasie drin.

gruß

niedersachsen

[hallodu_st]

[posting]18.842.544 von Pumafreddy am 16.11.05 17:42:48[/posting]Ich habe schon öfteres Gewinne mitgenommen, und bin dann wieder Billiger rein, meine derzeitigen Positionen:

1,38 (seufz) 2 K
1,20 (seufz) 1 K
1,02 1 K
0,89 2 K

Ein paar Cent noch und ich habs wieder,...

Facts: Wir bleiben an der Nasdaq (sehr Wichtig)
Oral-Lyn wird bald verstärkt produziert, deswegen wurden neue Anlagen bestellt
Oral-Lyn wird seit 2 Wochen am Latein-Amerikanischen Markt bereits verkauft, da dort zugelassen wurde
China vergibt Millionenförderungen wg. Vogelgrippe-Bekämpfung und Gen ist vorne mit dabei...

Würde Sagen, nächste Woche wieder 1,40

LG

[hallodu_st]

Und noch weils nach oben geht
Realtime Nasdaq

Last Trade: 1.04
Trade Time: 12:10PM ET
Change: 0.10 (10.64%)
Prev Close: 0.94
Open: 1.00
Bid: 1.04 x 2400
Ask: 1.04 x 11700
1y Target Est: N/A

Day`s Range: 0.98 - 1.05
52wk Range: 0.51 - 1.51
Volume: 4,244,278
Avg Vol (3m): 2,842,870
Market Cap: 48.70M
P/E (ttm): N/A
EPS (ttm): -0.66
Div & Yield: N/A (N/A)

[hallodu_st]

Das Tal der Tränen ist vorbei: 300 Mio $ Umsatz in südamerika lt. Amerikanischen Board!!!

[hallodu_st]

Meldung aus Ami-Board Kopiert:

NEWS - REPOSTED
by: johnkojan 11/28/05 02:53 pm
Msg: 39962 of 39997

DJ Generex, Pharmabrand To Produce Oral Insulin For Lat Am

11/28/2005
Dow Jones News Services
(Copyright © 2005 Dow Jones & Company, Inc.)



QUITO (Dow Jones)--Canada`s Generex Biotechnology (GNBT) and Ecuador`s Pharmabrand SA will next year start production of oral insulin for export within Latin America.

With an initial investment of $22 million to manufacture the drug in Ecuador, "Oral-lyn," as the spray will be called, took Generex about 10 years to develop.

"We will be the first in the world to make it and the first to market oral insulin - first in Ecuador, and then progressively throughout Latin America," Pharmabrand President Roberto Cid told reporters.

Generex head Anna Gluskin said the company chose Ecuador given its strategic location, facilitating distribution of the drug throughout the region.

The Oral-lyn will be made in a Pharmabrand pharmaceuticals plant located in Quito, which is one of the most modern facilities in Ecuador.

The companies also hope to receive permission to sell the products elsewhere in Latin America, starting in the second half of next year. That includes selling first in Colombia, Venezuela, Bolivia and Peru, where common Andean region regulations exist, and then later in Brazil, Mexico, Chile and Argentina.

The companies forecast sales in all of Latin America of some $300 million a year.


-By Mercedes Alvaro, Dow Jones Newswires; 5939-9728-653; [e-mail]


(END) Dow Jones Newswires

11-28-05 1412ET